Fidelity Investments
VTVT icon

Fidelity Investments’s vTv Therapeutics VTVT Stock Holding History

Fidelity Investments’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8M Hold
260,391
– – ﹤0.01% 2140
2026
Q1 		$10.3M Sell
260,391
-8,465
-3% -$307K ﹤0.01% 2031
2025
Q4 		$10.8M Buy
268,856
+75,965
+39% +$2.11M ﹤0.01% 2005
2025
Q3 		$4.49M Buy
192,891
+14,691
+8% +$258K ﹤0.01% 2274
2025
Q2 		$2.63M Hold
178,200
– – ﹤0.01% 2391
2025
Q1 		$3.09M Hold
178,200
– – ﹤0.01% 2317
2024
Q4 		$2.43M Hold
178,200
– – ﹤0.01% 2380
2024
Q3 		$2.4M Buy
+178,200
New +$2.96M ﹤0.01% 2347
2024
Q2 		– Sell
-11
Closed -$259 – 5659
2024
Q1 		$259 Buy
+11
New +$140 ﹤0.01% 4902
2023
Q4 		– Hold
0
– -$3 – 5670
2023
Q3 		– Sell
-130
Closed -$3.18K – 5241
2023
Q2 		$3.83K Buy
130
+128
+6,400% +$4.07K ﹤0.01% 4437
2023
Q1 		$61 Sell
2
-11
-85% -$373 ﹤0.01% 4949
2022
Q4 		$326 Hold
13
– – ﹤0.01% 4785
2022
Q3 		$0 Sell
13
-2
-13% -$79 ﹤0.01% 5453
2022
Q2 		$0 Buy
+15
New +$385 ﹤0.01% 5526
2019
Q3 		– Sell
-25
Closed -$1K – 4269
2019
Q2 		$1K Buy
+25
New +$1.5K ﹤0.01% 3652
2018
Q2 		– Sell
-7,396
Closed -$1.2M – 2715
2018
Q1 		$1.2M Buy
+7,396
New +$1.81M ﹤0.01% 2426
2016
Q4 		– Sell
-8,750
Closed -$2.52M – 2715
2016
Q3 		$2.52M Sell
8,750
-385
-4% -$92.7K ﹤0.01% 2332
2016
Q2 		$2.12M Hold
9,135
– – ﹤0.01% 2372
2016
Q1 		$1.89M Hold
9,135
– – ﹤0.01% 2401
2015
Q4 		$2.49M Hold
9,135
– – ﹤0.01% 2371
2015
Q3 		$2.38M Buy
+9,135
New +$3.18M ﹤0.01% 2375

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments's VTVT Position: Q2 2026 in Review

Fidelity Investments held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 260,391 shares worth $9.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

Fidelity Investments first reported a position in VTVT in Q3 2015 and has held it in 21 quarters since. The position peaked at $10.8M in Q4 2025. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Fidelity Investments held 260,391 shares of vTv Therapeutics worth $9.8M as of Q2 2026.
  • Fidelity Investments left its vTv Therapeutics share count unchanged in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2140 holding.
  • Fidelity Investments first reported a position in vTv Therapeutics in Q3 2015 and has held it in 21 quarters since.
  • Fidelity Investments's vTv Therapeutics position peaked at $10.8M in Q4 2025.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.